Phosphorylation of histone H2A or H2AX is an early and sensitive marker of DNA damage in eukaryotic cells, although mutation of the conserved damage-dependent phosphorylation site is well tolerated. Here, we show that H2A phosphorylation is required for cell-cycle arrest in response to DNA damage at the G1/S transition in budding yeast. Furthermore, we show that the tandem BRCT domain of Rad9 interacts directly with phosphorylated H2A in vitro and that a rad9 point mutation that abolishes this interaction results in in vivo phenotypes that are similar to those caused by an H2A phosphorylation site mutation. Remarkably, similar checkpoint defects are also caused by a Rad9 Tudor domain mutation that impairs Rad9 chromatin association already in undamaged cells. These findings indicate that constitutive Tudor domain-mediated and damage-specific BRCT domain-phospho-H2A-dependent interactions of Rad9 with chromatin cooperate to establish G1 checkpoint arrest.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1973948 | PMC |
| http://dx.doi.org/10.1038/sj.embor.7401036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protein-folding chaperone HSP90 buffers genetic variation in diverse organisms, but the clinical significance of HSP90 buffering in disease remains unclear. Here, we show that HSP90 buffers mutations in the BRCT domain of BRCA1. HSP90-buffered mutations encode protein variants that retain interactions with partner proteins and rely on HSP90 for protein stability and function in cell survival.
View Article and Find Full Text PDFDecoding protein dynamicity in DNA ligase activity through deep learning-based structural ensembles.
bioRxiv
November 2024
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037 USA.
Numerous proteins perform their functions by transitioning between various structures. Understanding the conformational ensembles associated with these states is essential for uncovering crucial mechanistic aspects that regulate protein function. In this study, we utilized AlphaFold3 () to investigate the structural dynamics and mechanisms of enzymes involved in DNA homeostasis, using NAD-dependent Taq ligases and human DNA Ligase 1 as a case example.
View Article and Find Full Text PDFUsing AI-predicted protein structures as a reference to predict loss-of-function activity in tumor suppressor breast cancer genes.
Comput Struct Biotechnol J
December 2024
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.
Article Synopsis
- The classification of missense variants in tumor suppressor genes related to breast cancer is complicated due to their rarity, leading to uncertainty in clinical decisions.
- This study utilizes generative AI to create high-resolution protein structures, which are then analyzed for protein stability changes to assess loss-of-function (LOF) activity in specific domains of the protein.
- Results show that AI-generated structures of the BRCA1-C terminal and DNA-binding domains significantly improve LOF activity prediction compared to experimental structures, indicating the potential of AI in this area of genetic research.
Phosphorylation of BRCA1 at serine 1387 plays a critical role in cathepsin S-mediated radiation resistance via BRCA1 degradation and BCL2 stabilization.
Biochim Biophys Acta Mol Basis Dis
January 2025
Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. Electronic address:
There is evidence that BRCA1, particularly cytoplasmic BRCA1, plays a significant role in initiating apoptosis through various mechanisms. Maintaining the stability of BRCA1 in cancer cells may be a promising therapeutic strategy for breast cancer, especially in cases of triple-negative breast cancer (TNBC) lacking appropriate therapeutic targets. Previously, it was reported that cathepsin S (CTSS) interacts with the BRCT domain of BRCA1, leading to ubiquitin-mediated degradation.
View Article and Find Full Text PDFEfficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type.
Front Oncol
September 2024
Department of Medical Oncology, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Article Synopsis
- This study examines the effectiveness of Poly ADP-ribose polymerase inhibitors (PARPi) in patients with BRCA mutations undergoing treatment for advanced ovarian cancer.
- A retrospective analysis of 79 patients revealed no significant differences in progression-free survival (PFS) based on specific BRCA domain defects or mutation types.
- The findings suggest that the success of PARPi maintenance treatment is largely independent of the BRCA defects or mutations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!